New study offers hope for a rare and devastating eye cancer
Researchers have found a treatment that works on some patients and, more importantly, a tool that can predict when it is likely to succeed.
Source: washingtonpost.com
📰 Ryanj Sullivan News
Ryanj Sullivan News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ryanj Sullivan. Real-time updates on events, politics, business and more.
Study Reinforces BRAF-MEK Inhibition Over Anti-BRAF Only in Advanced Melanoma
Improved PFS with encorafenib-binimetinib versus encorafenib, but immunotherapy still top option
United States Ryanj Sullivan Paoloa Ascierto Charles Bankhead Hospital Cancer Center Istituto Nazionale
Source: medpagetoday.com
Dr Sullivan on the Reduction of ctDNA With Tebentafusp in Metastatic Uveal Melanoma
Ryan J. Sullivan, MD, discusses the early reduction of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp and shares how these reductions could correlate with longer overall survival in patients with a best response of stable disease.
Source: onclive.com
Early ctDNA Testing Provides Another Tool for Predicting Survival Outcomes With Tebentafusp in Metastatic Uveal Melanoma
Ryan J. Sullivan, MD, discusses previous research on tebentafusp in uveal melanoma that led to the inception of the IMCgp100-202 trial and clinical implications for data confirming the predictive value of circulating tumor DNA levels.
United States Ryanj Sullivan Harvard Medical School Bristol Myers Squibb Melanoma Program At Massachusetts Melanoma Program
Source: onclive.com
Dr Sullivan on Pseudoprogression as a Potential Explanation for Outcomes With Tebentafusp in Uveal Melanoma
Ryan J. Sullivan, MD, explains the prolongation of survival with tebentafusp-tebn despite apparent initial radiographic tumor progression in patients with uveal melanoma.
United States Ryanj Sullivan Harvard Medical School Massachusetts General Hospital Patients With Uveal Melanoma Treated Tebentafusp
Source: onclive.com
Dr Sullivan on ctDNA Reduction After Tebentafusp Treatment in Uveal Melanoma
Ryan J. Sullivan, MD, discusses findings from a study investigating the effects of early circulating tumor DNA reduction on overall survival in patients with uveal melanoma treated with tebentafusp.
United States Ryanj Sullivan Harvard Medical School Massachusetts General Hospital Patients With Uveal Melanoma Treated Tebentafusp
Source: onclive.com
Study Suggests Narrow Excision Margins Safe for Early Melanoma
The results "support the need for prospective randomized clinical trials to definitively answer the important question about appropriate excision margins for T1a melanoma," the investigators write.
United States Ryanj Sullivan Andrea Maurichi Gemme Rouge Cancer Center National Cancer Institute Of Milan
Source: medscape.com
Moderna, Inc.: Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting
CAMBRIDGE, MA / ACCESSWIRE / March 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157/V940
Source: finanznachrichten.de
Acetaminophen Blunts Antitumor Activity of Immunotherapy
Lower response rates, worse survival seen in patients with detectable levels of the antipyretic
Source: medpagetoday.com